Newsroom
Contact us
FAQ
Íslenska
  • Company
  • For investors
  • Biosimilars
  • Corporate Sustainability
  • Careers
  • About Us
  • Media Center
  • Careers
  • Newsroom
  • Contact us
  • Terms of Use
  • Privacy Policy
  • Cookie Policy

Alvotech 2025. All rights reserved.

Company Announcement
16 November 2022

Alvotech Secures Financing Facilities of Approximately $136 Million

Existing senior bonds upsized by $70 million with additional investment from a consortium of institutional investorsAlvotech acquires the Reykjavik manufacturing facility, previously utilized...
Company Announcement
16 November 2022

Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update

Revenue for first nine months of 2022 increased to $59.2 million, compared to $2.0 million for the same period in 2021Discussions with U.S. FDA progressed regarding both biologic license applications...
Company Announcement
14 November 2022

Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira®

Increases availability of cost-effective high-concentration low-volume adalimumab in AustraliaFirst approved biosimilar from the partnership with Cipla, which also includes four other biosimilar...
Company Announcement
10 November 2022

Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference

Alvotech will present two posters and will be featured in an Ignite Talk related to its switching study for ATV02The switching study was conducted to investigate the pharmacokinetics,...
Company Announcement
27 October 2022

Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...
Company Announcement
26 October 2022

Alvotech to Participate in Upcoming Jefferies London Healthcare Conference in November

Alvotech (NASDAQ: ALVO), a global biotech specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of the leadership team will...
Company Announcement
19 October 2022

Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care

Expanded partnership covers biosimilar candidates in immunology and oncology Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar...
Company Announcement
17 October 2022

Alvotech’s Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner...
Company Announcement
11 October 2022

Alvotech Appoints Sarah Tanksley as Chief Quality Officer

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Sarah Tanksley will join its...
Managers’ Transactions
27 September 2022

Attached is an announcement on transactions of managers and closely associated persons.

1…2425…32